We demonstrated that the plasma amiloride level was sufficient in inhibiting NHE1 in AML cells, leading to intracellular acidification and apoptosis in combination with tyrosine kinase inhibitors and chemotherapy. This evidence concerns the gene SLC9A1 and acute myeloid leukemia.